Download PQ62519 attached document

Drug
Disease
Crizotinib
Non-SmallCell Lung
Carcinoma
Cetuximab
Head and
Neck
Cancers
Pemetrexed
Non-SmallCell Lung
Carcinoma
Dasatinib
Dasatinib
Chronic
Myeloid
Leukaemia
Chronic
Myeloid
Leukaemia
Indication
In second and
subsequent line
anaplastic
lymphoma kinase
(ALK)-positive
advanced nonsmall lung cancer
1st line treatment
of metastatic
and/or recurrent
squamous cell
carcinoma of the
head and neck
Maintenance
treatment of
stage IIIB/IV nonsquamous nonsmall cell lung
cancer after
response to
pemetrexedcontaining first
line therapy
Treatment of
CML which is
refractory or
significant
intolerance to
imatinib and
intolerance to
nilotinib
Untreated CML
Status
Publication
date
12 month
cost impact
Published
Dec-16
(<£1m p/a
100
for England)
Mar-17
Not recommended in Appraisal
Consultation Document (ACD)
(published January 2017)
Aug-16
£6.3m
(based on
list price).
Around 690
eligible and 570
estimated to take
up treatment
each year.
Dec-16
£3.7m
based on
list price
and
assumption
that
number of
people
treated
increases
from 430 to
550.
550
Dec-16
Around 530
people per year
(<£1m p/a
eligible to start
for England)
1st line treatment
each year.
In
developm
ent
Published
Published
Published
Population in first
12 months
Sorafenib
Trastuzumab
Emtansine
Radium 223
Ibrutinib
Cabazitaxel
Brentuximab
Hepatocellu
lar
carcinoma
(HCC)
1st line HCC
In
developm
ent
Mar-17
Not
available
Breast
Cancer
Treatment of
HER2-positive
locally
advanced/unrese
ctable or
metastatic (Stage
IV) breast cancer
who previously
received
trastuzumab and
a taxane,
separately or in
combination
In
developm
ent
Mar-17
Not recommended at appraisal
(published Jan '17)
Prostate
Cancer
Treatment of
hormonerelapsed prostate
cancer patients
with bone
metastases
Published
Sep-16
£9.0m
Lymphoma
Treatment of
relapsed/
refractory mantle
cell lymphoma
In
developm
ent
To be
confirmed
Not recommended at appraisal
(published Jan '17)
Prostate
Cancer
2nd or 3rd line
metastatic
castration
resistant prostate
cancer
Published
May-16
Not avilable
Lymphoma
Treatment of
relapsed/
refractory
In
anaplastic large
developm
cell lymphoma
ent
where no other
salvage treatment
is available
May-17
Not recommended at appraisal
(published Dec '16)
Data not yet
available
360
370